KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Resmed (RMD) Gross Margin (2016 - 2025)

Resmed's Gross Margin history spans 17 years, with the latest figure at 61.76% for Q4 2025.

  • For Q4 2025, Gross Margin rose 316.0% year-over-year to 61.76%; the TTM value through Dec 2025 reached 60.87%, up 248.0%, while the annual FY2025 figure was 59.36%, 269.0% up from the prior year.
  • Gross Margin reached 61.76% in Q4 2025 per RMD's latest filing, roughly flat from 61.46% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 61.76% in Q4 2025 to a low of 54.44% in Q3 2023.
  • Average Gross Margin over 5 years is 57.54%, with a median of 57.02% recorded in 2022.
  • Peak YoY movement for Gross Margin: tumbled -247bps in 2023, then surged 414bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 56.36% in 2021, then fell by 0bps to 56.08% in 2022, then dropped by -1bps to 55.64% in 2023, then grew by 5bps to 58.6% in 2024, then increased by 5bps to 61.76% in 2025.
  • Per Business Quant, the three most recent readings for RMD's Gross Margin are 61.76% (Q4 2025), 61.46% (Q3 2025), and 60.84% (Q2 2025).